



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07F 9/11, 9/117, 9/12, 9/655	A1	(11) International Publication Number: WO 00/69865 (43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/AU00/00452 (22) International Filing Date: 12 May 2000 (12.05.00) (30) Priority Data: PQ 0374 14 May 1999 (14.05.99) AU PCT/AU00/00038 25 January 2000 (25.01.00) AU (71) Applicant (for all designated States except US): SWIG PTY LTD [AU/AU]; Greenberg & Co., 1250 Malvern Road, Malvern, VIC 3144 (AU). (72) Inventor; and (75) Inventor/Applicant (for US only): WEST, Simon, Michael [AU/AU]; 3 Verdon Street, Williamstown, VIC 3016 (AU). (74) Agent: MCMASTER OBERIN ARTHUR ROBINSON & HEDDERWICKS; 530 Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: IMPROVED PROCESS FOR PHOSPHORYLATION AND COMPOUNDS PRODUCED BY THIS PROCESS		
(57) Abstract A process for phosphorylating primary fatty alcohols, secondary alcohols, or aromatic alcohols comprising the following steps: (a) forming an intimate mixture of one or more of the above alcohols and P ₄ O ₁₀ or partly hydrated P ₄ O ₁₀ or a mixture thereof at a temperature below 80 °C; and (b) allowing the intimate mixture to continue to react for a period of time at a temperature below 80 °C until the formation of the dihydrogen form of the phosphorylated alcohol is substantially formed.		

Best Available Copy

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Improved Process For Phosphorylation And Compounds Produced By This Process

Field of the invention

The invention relates to an improved process for phosphorylation of organic hydroxyl groups and the compounds produced using this process.

5 Background of the invention

Whilst the following discussion highlights the invention with respect to dietary supplements, it is believed that the same principles apply to other compounds containing organic hydroxyl groups such as pharmaceutical compounds with hydroxyl groups.

10 The use of dietary supplements is well known, for example hormones, phytosterols or chromans. One of the problems encountered with such supplements for human ingestion is that many of the supplements are relatively water insoluble but the human digestive tract is a substantially aqueous system. Previous attempts to overcome this problem include using emulsifiers to enable an oil-based solution of the supplement to combine with an aqueous system and thus maintain the supplement's bioavailability. Consequently, it would be
15 useful to be able to convert these dietary supplements to water soluble compounds without disturbing their inherent structure. Phosphate salts with either potassium or sodium are already found in biological tissue. Therefore phosphate salts should be tolerated by the body.

20 There is a diverse art for the production of organic phosphates, however none of these methods are considered to be suitable for production of complex phosphate compounds because they are either unsuitable for use on a commercial scale or there are side reactions which produce undesired by-products.

Ordinarily, phosphorylation reagents and methods are chosen to avoid significant degradation of the compound being phosphorylated. Where gentle conditions are required,
25 then reagents such as 2:2:2-trichloroethyl dichlorophosphate, di-imidazolidine chlorophosphate and di-analide chlorophosphate have been employed but have limited yields which are inadequate for commercial processes. When more severe conditions are feasible, then phosphorous oxychloride has been used, but the reaction produces a variety of by-products together with hydrogen chloride. There are other problems associated with

the fact that phosphorous oxychloride is difficult to manage which make this reagent unsuitable for use on a commercial scale.

Although P_4O_{10} [which is often incorrectly called phosphorous pentoxide] has been used for phosphorylation of ethanol and other short chain primary alcohols, it has not been used for higher alcohols and complex molecules because the temperatures used are too high and there is considerable degradation. Another reason why P_4O_{10} is not used for higher alcohols and complex molecules is that at the higher temperatures used in known P_4O_{10} processes, there is formation of a significant amount of by-products. Even with ethanol, there is a significant amount of diethylphosphate as well as monoalkylphosphate which is produced and these substances must be removed. Commercial processes use P_4O_{10} with ethanol but there is a complicated clean-up procedure because the reaction occurs at a high temperature.

Further, with secondary or tertiary alcohols P_4O_{10} causes dehydration and formation of a double bond. This dehydration is further promoted by the high temperatures at which this reaction takes place. In fact, this is a standard reagent and method for forming a double bond. This reaction has thus been considered to be unsuitable for production of complex phosphate compounds.

It is the need for lower temperatures which has led to the use of $POCl_3$ because, in the presence of a base, a lower temperature can be used and degradation is avoided. $POCl_3$ is the preferred method for phosphorylating complex molecules.

There is, therefore, a need for a reliable process for phosphorylating complex compounds so that these compounds can be used in aqueous environments.

Summary of the invention

It has surprisingly been found that P_4O_{10} can be used to phosphorylate primary fatty alcohols, secondary alcohols (including cyclohexanols) and aromatic alcohols (including phenols and chromanols). In this description and in the claims, the term "complex alcohols" refers to primary fatty alcohols, secondary alcohols and aromatic alcohols. Further, similar results may be found with partly hydrated P_4O_{10} which is commonly called polyphosphoric acid.

The complex alcohols include hormones, phytosterols, tocopherols (chromans), vitamin K1 and other oil-soluble vitamins and dietary supplements as well as pharmaceutical compounds such as Amoxycillin.

In this description, the word "intimate" is used to signify its technical meaning as known to persons skilled in the art. That is, to signify that two substances are in very close physical contact dispersed as particles which are as small as possible so that a reaction is initiated. There must be as large a surface area as possible for the reaction to initiate and this is also advantageous for further reaction.

Accordingly, there is provided a process for phosphorylating complex alcohols comprising the following steps:

- (a) forming an intimate mixture of one or more complex alcohols and P_4O_{10} or partly hydrated P_4O_{10} or a mixture thereof at a temperature below $80^{\circ}C$; and
- (b) allowing the intimate mixture to continue to react for a period of time at a temperature below $80^{\circ}C$ until the formation of the dihydrogen form of the phosphorylated complex alcohol is substantially completed.

It is understood that in steps (a) and (b), the temperature is sufficient to ensure there is minimum degradation of the complex alcohols but the reaction will still proceed to a satisfactory extent.

The complex alcohols must either be in a liquid phase or in solution for the reaction to proceed. If the complex alcohols are not liquid at the desired temperature of reaction, the complex alcohols will need to be dissolved in a solvent in which P_4O_{10} is also soluble.

Preferably, where minimum degradation is desired, the temperature at which the reaction is performed is in the range from 0 to $50^{\circ}C$. More preferably, the temperature is in the range from 0 to $40^{\circ}C$.

Preferably where the period of time in step (b) is minimized, the temperature at which the reaction is performed is about $70^{\circ}C$.

The ratio of P_4O_{10} to complex alcohols will depend on the temperature at which the reaction occurs. At the higher temperatures, the ratio of phosphorus to complex alcohols is substantially equimolar. That is, at the higher temperatures there is more efficient

consumption of the phosphate groups. At the lower temperatures, the ratio of P_4O_{10} to complex alcohols is substantially equimolar.

The period of time in step (b) is dependent on the temperature at the ratio of reagents. Where there is equimolar phosphorus, preferably the period of time does not exceed about 30 minutes. Where there is equimolar P_4O_{10} , preferably the period of time does not exceed about 10 minutes.

The choice of temperature at which the reaction occurs is dependent on the expense of the complex alcohols. For example, Amoxycillin is expensive therefore it is preferable to minimize the degradation of Amoxycillin.

10 Where lower temperatures are used and there are unreacted reagents, the unreacted reagents can be recycled. For example, if the temperature is between 0 to 40°C, the process would further comprise a step where the unreacted reagents were mixed with more P_4O_{10} and complex alcohol and steps (a) and (b) repeated.

15 The phosphorylated complex alcohols may be recovered as either the acid or as a salt (usually potassium or sodium) using methods known to those skilled in the art. For example, the reaction mixture from step (b) may be neutralized with potassium or sodium hydroxide then the water evaporated to recover the salt.

The pressure is typically at atmospheric because there is no advantage using higher pressures at these temperatures.

20 The intimate mixture is formed using methods known to those skilled in the art. Vigorous stirring is typically necessary to achieve an intimate mixture. In a laboratory, a mortar and pestle can be used. In an industrial plant, a high shear mixer would be used.

According to a preferred embodiment, formation of the intimate mixture in step (a) is performed in the presence of an aliphatic carboxylic acid excluding formic and acetic acid.

25 In this description and in the claims, the term "aliphatic acid" refers to any aliphatic carboxylic acid except for formic acid and acetic acid. Preferably, the aliphatic acid is a free fatty acid. Examples include oleic acid and stearic acid. The aliphatic acid acts as a catalyst for the reaction and reduces the side reactions. Preferably, where a solvent is used to dissolve the complex alcohols, the solvent is a free fatty acid.

According to another form of the invention, there is provided a phosphate derivative of a complex alcohol which was produced by the above process.

Examples

The invention will now be further explained and illustrated by reference to the following
5 non-limiting examples.

Example 1

P_4O_{10} (0.28 g) was added to 1-dodecanol (0.18 g) and stearic acid (0.02g). The mixture was stirred vigorously for 5 mins at 20-25°C. The product was analyzed by electrospray mass spectrometry which showed the formation of 1-dodecanol phosphate.

10 Example 2

A phytosterol extract containing mainly beta sitosterol, stigmasterol and campesterol (0.4g) was mixed with polyphosphoric acid (0.8g) at 20-25°C by grinding in a mortar and pestle for 0.5 hours then let stand for 12 hours at ambient temperature. The product was diluted with acetonitrile and then analyzed by spray mass spectrometry which showed that the
15 mono-phosphates of the sterols were present.

Example 3

17 beta-estradiol (0.27g) was mixed with polyphosphoric acid (0.3g) at 20-25°C in a mortar and pestle for 0.5 hours then let stand for 12 hours at ambient temperature. The product was diluted with acetonitrile and analyzed by spray mass spectrometry which
20 showed that 17 beta-estradiol monophosphate had been formed.

Example 4

Alpha-phyloquinone (or vitamin K1) (0.45g in 5g oleic acid) was mixed with P_4O_{10} at 20-25°C in a mortar and pestle for 0.5 hours then let stand for 12 hours at ambient temperature. The product was analyzed which showed that the mono-phosphate was
25 formed.

Example 5

P_4O_{10} (165.1g) was added to tocopherol (1 kg) and stirred together for 30 minutes at 70°C. The mixture discoloured to give a brown/black material which became very viscous. The material was then mixed vigorously with a mechanical stirrer for 30 minutes in water (10 l) to form a slurry. The slurry was then centrifuged, the water discarded, and the pellet collected. The pellet was then dissolved in AR ethanol (10 l). Then sodium (160.4 g) was added slowly to the solution and stirred by a magnetic stirrer. The mixture was then filtered, resuspended in AR ethanol (10 l) and heated to reflux, so dissolving the unreacted tocopherol and fatty acid. The hot dispersion was cooled and filtered to recover di-sodium tocopherol phosphate.

Example 6

P_4O_{10} (3.0g) was added to a mixture of dopamine hydrochloride (2.0g) and stearic acid (0.04g), then mixed together. To the resulting heterogeneous solid was added water (0.3-0.5 ml), causing an exothermic reaction (~50°C). The resulting slurry was stirred for 2-3 minutes, then water (50 ml) was added completely dissolving the mixture. The mixture was analyzed using electro-spray mass spectrometry to find dopamine phosphate and inorganic phosphates.

Example 7

The above procedure (example 6) was repeated with amoxicillin trihydrate (2g), stearic acid (0.04g) and P_4O_{10} (1.4g). The product mixture contained Amoxicillin phosphate and inorganic phosphates.

Example 8

The above procedure (example 6) was repeated with cholesterol (2.0g), stearic acid (0.04g) and P_4O_{10} (1.5g). The reaction mixture was dispersed into water (50 ml) then centrifuged to recover the cholesterol phase. This phase was analyzed and was found to contain unreacted cholesterol and cholesterol phosphate.

The novel process for phosphorylation has been successfully used for a variety of useful compounds and would be understood by those skilled in this art to have an obviously wider application.

The word 'comprising' and forms of the word 'comprising' as used in this description and in the claims does not limit the invention claimed to exclude any variants or additions.

Modifications and improvements to the invention will be readily apparent to those skilled in the art. Such modifications and improvements are intended to be within the scope of this
5 invention.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A process for phosphorylating complex alcohols comprising the following steps:
 - (a) forming an intimate mixture of one or more complex alcohols and P_4O_{10} or partly hydrated P_4O_{10} or a mixture thereof at a temperature below $80^{\circ}C$; and
 - 5 (b) allowing the intimate mixture to continue to react for a period of time at a temperature below $80^{\circ}C$ until the formation of the dihydrogen form of the phosphorylated complex alcohol is substantially completed.
2. A process according to claim 1 wherein the temperature in steps (a) and (b) is in the range from 0 to $50^{\circ}C$.
- 10 3. A process according to claim 2 wherein the temperature in steps (a) and (b) is in the range from 0 to $40^{\circ}C$.
4. A process according to claim 1 wherein the temperature in steps (a) and (b) is about $70^{\circ}C$.
5. A process according to any one of claims 1 or 4 wherein the ratio of phosphorus to complex alcohols is substantially equimolar.
- 15 6. A process according to any one of claims 2 or 3 wherein the ratio of P_4O_{10} to complex alcohols is substantially equimolar.
7. A process according to claim 5 wherein the period of time in step (b) does not exceed about 30 minutes.
- 20 8. A process according to claim 6 wherein the period of time in step (b) does not exceed about 10 minutes.
9. A process according to any one of the preceding claims wherein the intimate mixture in step (a) is formed in the presence of an aliphatic acid.
10. A process according to claim 9 wherein the aliphatic acid is a free fatty acid.
- 25 11. A phosphate derivate of a complex alcohol which was produced according to any one of the above claims.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00452**A. CLASSIFICATION OF SUBJECT MATTER**Int. Cl. ⁷: C07F 9/11, 9/117, 9/12, 9/655

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
C07F 9/-

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
DERWENT: C07F/- and (phosphorous pentoxide or polyphosphoric acid or phosphoric anhydride or diphosphorus pentoxide or phosphorus oxide or P4O10 or P2O5)
CHEMICAL ABSTRACTS: phosphorylation/ct and 1314-56-3/m**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 141 938 (KLOSE) 27. February 1979 Examples	1-11
X	US 4 874 883 (UPHUES et al.) 17 October 1989 Examples	1-11
X	US 5 138 084 (CASAGRANDE et al.) 11 August 1992 Examples	1-11

☒ Further documents are listed in the continuation of Box C ☒ See patent family annex

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
14 July 2000Date of mailing of the international search report
25 JUL 2000Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200, WODEN ACT 2606, AUSTRALIA
E-mail address: pct@ipaaustralia.gov.au
Facsimile No. (02) 6285 3929Authorized officer

JAMIE TURNER
Telephone No : (02) 6283 2071

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00452

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 554 781 (REIERSON) 10 September 1996 Examples	1-11
X	Derwent Abstract Accession no. 97-061803/06, Class B05 D21 E11, JP 08311085 (KAO CORP) 26 November 1996	1-11
X	Derwent Abstract Accession no. 96-397241/40, Class E11, JP 08193089 (KAO CORP) 30 July 1996	1-11
X	Derwent Abstract Accession no. 96-055975/06, Class D25 E11 F06, JP 073116170 (KAO CORP) 5 December 1995	1-11
X	Derwent Abstract Accession no. 87-281015/40, Class B02, JP 62195393 (YAKULT HONSHA KK) 28 August 1987	1-11
X	Derwent Abstract Accession no. 84-259538/42, Class E11, JP 59157091 (SANYO CHEM IND LTD) 6 September 1984	1-11
X	Patent Abstracts of Japan JP 10-045783 (SHOWA DENKO KK) 17 February 1998 abstract	1-11

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00452

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	4141938	BE	859433	CH	635848	DE	2645211
		FR	2367078	GB	1545193	IT	1091147
		NL	7711058	SE	7710788		
US	4874883	DE	3702766	EP	276777	JP	63201194
US	5138084	CA	2030284	EP	430336	FI	905748
		IT	1236843	JP	3176495		
US	5554781	CA	2145837	CN	1125729	EP	675076
		JP	8041082				

END OF ANNEX

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/40033 A1

(51) International Patent Classification⁷: **A61K 31/662**,
9/107, A61P 17/16

(74) Agent: **ALLENS ARTHUR ROBINSON PATENT &
TRADE MARKS ATTORNEYS**; 530 Collins Street,
Melbourne, VIC 3000 (AU).

(21) International Application Number: PCT/AU01/01475

(22) International Filing Date:
14 November 2001 (14.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/247,997 14 November 2000 (14.11.2000) US
PR 5499 6 June 2001 (06.06.2001) AU

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **TO-COVITE PTY LTD** [AU/AU]; Level 2, 90 William Street, Melbourne, VIC 3000 (AU).

Published:

— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **WEST, Simon, Michael** [AU/AU]; 3 Verdon Street, Williamstown, VIC 3016 (AU).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/40033 A1

(54) Title: FORMULATION CONTAINING PHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS

(57) Abstract: There is provided an emulsion composition for therapeutic administration comprising: (a) at least one mono-electron transfer agent phosphate derivative; (b) at least one di-electron transfer agent phosphate derivative; wherein the amount of mono-electron transfer agent phosphate derivatives is no less than equimolar to the amount of di-electron transfer agent phosphate; and (c) a suitable carrier.

Formulation Containing Phosphate Derivatives of Electron Transfer Agents

Field of the invention

The invention relates to a therapeutic formulation containing phosphate derivatives of electron transfer agents. More particularly, this invention relates to a therapeutic formulation containing mono-electron transfer agent phosphate derivatives and di-electron transfer agent phosphate derivatives.

The invention also relates to a detergent composition containing surface active agents.

Background of the invention

In this specification, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not to be taken as an admission that the document, act or item of knowledge or any combination thereof was at the priority date:

- (a) part of common general knowledge; or
- (b) known to be relevant to an attempt to solve any problem with which this specification is concerned.

Whilst the following discussion concerns tocopherol and dermal therapy, it is also to be understood that the same principles apply to any application in which a therapeutic formulation containing electron transfer agents may be used.

The skin is the largest organ of the body, and, among other things, functions to protect the internal organs from external chemical, physical and pathological hazards. Normal skin is composed of an outer epidermis covering sub dermal layers, where each layer comprises different sections. The outer cornified layer of the epidermis possesses properties of strength, flexibility, high electrical impedance and dryness that retards penetration and proliferation of microorganisms. The cornified protective layer is formed by the migration of maturing keratinocytes that are formed at the junction of the dermis and epidermis.

Vitamin E (tocopherol) is an essential part of skin dynamics and is known to be very important for skin health, with deficiency manifesting as a cornified, scaly delicate skin, thickened epidermis, scaling, lesions, chronic infection, inflammation and erythema. Vitamin E is the main naturally occurring lipid soluble agent protecting the skin from stress, and is the main lipid soluble agent protecting the cell membrane lipids from peroxidation.

Skin is subject to constant stress due to exposure to everyday elements – sun, wind and water. As a result, it is common for many topical personal care products such as lotions, moisturizers, shampoo and conditioners to contain vitamin E in various forms to assist in maintaining skin health. In order to assist in maintaining skin health, it is necessary for the vitamin E to reach the target area of the dermis. The most direct method of achieving this targeting is to apply a topical formulation to the affected area. However, topical application of vitamin E to the skin using current formulations has variable success due to the skin's ability to erect an impenetrable barrier to many outside elements. It is critical to provide for the penetration of vitamin E through the epidermis to the dermis.

10 The use of free tocopherol is avoided because it is unstable, therefore suitable derivatives must be found. In the alimentary canal, it has been found that there is lipase activity which releases free tocopherol from the esters of tocopherol, typically the acetate ester. This lipase activity enables the use of tocopheryl acetate as a nutritional source of Vitamin E.

15 In contrast, the surface of the skin is deficient in lipase activity unless it is infected with microorganisms that are able to digest sebaceous excretions. Thus tocopheryl acetate must first diffuse through the epidermis into the vital derma, where the cells have a very limited lipase activity which releases the Vitamin E. It is believed that topical formulations using tocopherol acetate have not been able to deliver adequate tocopherol beyond the epidermal layers, and therefore provide little benefit. Since tocopheryl acetate is a lipidic material requiring formulation with an oil in water emulsion, absorption from such a formulation is less than optimal.

20 The epidermis is permeable to water soluble substances, such as tocopheryl phosphate. Until now producers of formulations containing tocopheryl phosphate utilized mono-tocopheryl phosphate isolated from the mixture produced during phosphorylation. The phosphorylation has been typically achieved using phosphorous oxychloride. The product was purified because it was believed that the by-products were deleterious to the efficacy of the mono-tocopheryl phosphate because not all the by-products were water soluble. The perceived deleterious effects were considered significant enough to justify the cost of complicated purification processes. Typically, the purification is performed by using ethanol to extract the di-tocopheryl phosphate and free tocopherol by-products.

Summary of the Invention

It has been found that the use of a non-purified or semi-purified electron transfer agent phosphorylation therapeutic product is efficacious. In particular, the non-water soluble di-electron transfer agent phosphate derivatives do not have a deleterious effect on the efficacy of the therapeutic product and may even provide a synergistic effect which results in beneficial properties which enhance the dermal penetration and/or efficacy of the mono-electron transfer agent phosphate derivatives.

According to a first aspect of the invention, there is provided an emulsion composition for therapeutic administration comprising the following:

- 10 (a) at least one mono-electron transfer agent phosphate derivative;
 - (b) at least one di-electron transfer agent phosphate derivative;
 - wherein the amount of mono-electron transfer agent phosphate derivative is no less than equimolar to the amount of di-electron transfer agent phosphate derivative; and
 - (c) a suitable carrier.
- 15 According to a second aspect of the invention, there is provided a method for administering to a subject electron transfer agent phosphate derivatives comprising the step of administering an emulsion composition comprising the following:
- (a) at least one mono-electron transfer agent phosphate derivative;
 - (b) at least one di-electron transfer agent phosphate derivative;
 - 20 wherein the amount of mono-electron transfer agent phosphate derivative is no less than equimolar to the amount of di-electron transfer agent phosphate derivative; and
 - (c) a suitable carrier.

The term "electron transfer agent" is used herein to refer to the class of chemicals which may be phosphorylated and which (in the non-phosphorylated form) can accept an electron to generate a relatively stable molecular radical or accept two electrons to allow the compound to participate in a reversible redox system. Examples of classes of electron transfer agent compounds that may be phosphorylated include hydroxy chromans including alpha, beta and gamma tocopherol, tocols and tocotrienols in enantiomeric and racemic forms; quinols being

the reduced forms of vitamin K1 and ubiquinone; hydroxy carotenoids including retinol; and ascorbic acid.

The phosphate derivatives of electron transfer agents comprise compounds covalently bound by means of an oxygen to the phosphorus atom of a phosphate group. The oxygen atom is typically derived from a hydroxyl group on the electron transfer agents. The phosphate derivative may exist in the form of a free phosphate acid, a salt thereof, a di-phosphate ester thereby including two molecules of electron transfer agent, a mixed ester including two different compounds selected from electron transfer agents, a phosphatidyl compound wherein the free phosphate oxygen forms a bond with an alkyl or substituted alkyl group, or a complex with a complexing agent selected from amphoteric surfactant, cationic surfactant, amino acids having nitrogen functional groups or proteins rich in these amino acids..

Examples of acceptable salts of mono-tocopherol phosphate derivatives are selected from the group consisting of the di-sodium, di-potassium, di-lithium, di magnesium, mono-sodium, mono-potassium, mono-lithium, or mono-magnesium salts or mixtures thereof. Preferably, the acceptable salts of di-tocopheryl phosphate derivatives are selected from the sodium, potassium, lithium or magnesium salts. The di-tocopheryl phosphate derivatives will usually only form a salt in the environment required to form the di-metal salts of mono-tocopheryl phosphate derivatives.

Preferably, the molar ratio of mono-electron transfer agent phosphate derivatives to di-electron transfer agent phosphate derivatives is in the range from 85:15 to 65:35. There must be enough di-electron transfer agent phosphate derivatives to form an emulsion and prevent the mono-electron transfer agent phosphate derivatives from going completely into solution, but not so much di-electron transfer agent phosphate derivatives that there is precipitation.

The mixture of mono-electron transfer agent phosphate derivatives and di-electron transfer agent phosphate derivatives can be prepared by recombining the purified individual components or by using the unpurified or semi-purified reaction product of a phosphorylation process. Preferably, the mixture is obtained by using the reaction product of a phosphorylation process. The source of a mixture of tocopheryl phosphate derivatives is preferably the reaction product of the phosphorylation of tocopherol using P_4O_{10} .

The term "acceptable carrier" is used herein to refer to a carrier considered by those skilled in the drug, food or cosmetic arts to be non-toxic when used to treat humans, animals or plant in parenteral or enteral formulations. The carrier chosen will depend on the route of

administration. Ingestible formulations includes tablets, capsules, powders, chewable tablets, capsules, oral suspensions, children's formulations, enteral feeds, nutraceuticals and functional foods. For a topical application, the carrier typically comprises hydrophilic substances such as water, glycerol, polyethyleneglycol, sorbitol or propanol. For example, the composition could be used as a shampoo, hair conditioner, moisturizing cream or lotion or lipstick as a topical application.

According to a third aspect of the invention, there is a process for preparing a therapeutic formulation containing phosphate derivatives of electron transfer agents comprising the steps of:

- 10 (a) phosphorylating one or more electron transfer agents using P_4O_{10} to form a mixture of at least one mono-electron transfer agent phosphate derivative and at least one di-electron transfer agent phosphate derivative;

wherein the amount of mono-electron transfer agent phosphate derivative is no less than equimolar to the amount of di-electron transfer agent phosphate derivative; and

- 15 (b) combining the mixture of mono-electron transfer agent phosphate derivative and di-electron transfer agent phosphate derivative with a suitable carrier.

The mono-electron transfer agent phosphate derivatives have good water solubility, therefore before they can be absorbed into the skin or hair an aqueous topically applied composition must dry. In contrast, di-electron transfer agent phosphate derivatives are not water soluble and cause the formation of an unstable emulsion when emulsified with water and other hydrophilic solvents. Without wishing to be bound by theory, it is noted that skin is hydrophobic so when the composition is spread onto the skin, the droplets in the emulsion are attracted to the skin. The micelles become unstable near a hydrophobic surface and break so the mono-electron transfer agent phosphate derivatives are released onto the skin. The mono-electron transfer agent phosphate derivatives can then diffuse through the epidermis into the derma. Therefore, di-electron transfer agent phosphate derivatives (once considered a nuisance by-product) function as an effective spreading agent for the mono-electron transfer agent phosphate derivatives.

Again, without wishing to be bound by theory, it is considered necessary for a product which is being ingested to have several types of surface activity including detergency and appropriate surface tension to facilitate absorption. Mono-electron transfer agent phosphate derivatives

may have strong detergency but do not have sufficient surface tension effects. Therefore, the mixture of mono-electron transfer agent phosphate derivatives and di-electron transfer agent phosphate derivatives having self-emulsification properties which include both types of surface activity, that is, strong detergency and strong surface tensions, will be better absorbed, especially in the small intestine.

It has surprisingly further been found that pure mono-tocopheryl phosphate and its salts are powerful surface active agents and detergents giving a stable foam.

According to a fourth aspect of the invention, there is provided a detergent composition comprising a surface active agent selected from the group consisting of mono-tocopheryl phosphate, its salts and mixtures thereof.

There is also provided a method of increasing the surface activity and detergency of a composition by adding a surface active agent selected from the group consisting of mono-tocopheryl phosphate, its salts and mixtures thereof.

Again, whilst not wishing to be bound by theory, it is thought that this detergent property may be due to the fact that mono-tocopheryl phosphate is in the form of a polar head and a non-polar tail. In contrast, di-tocopheryl phosphate has 2 non-polar tails and a polar central group which makes it surface active but it is not a detergent because at high concentrations it accumulates in the surface layer of the composition and acts as a foam breaker because the surface becomes predominantly non-polar.

Examples

The invention will now be further illustrated and explained by reference to the following non-limiting examples.

Example 1

In this example, a therapeutic formulation according to the invention was prepared using tocopherol as the electron transfer agent.

Preparation of the tocopheryl phosphate mixture

Take 500 g dl-alpha-tocopherol and mix with a high shear mixer 4 aliquots each of 21g of P_4O_{10} at 12 minute intervals, holding the temperature above 60°C. While the mixture is still hot, add over 1.5 hours 91.5 g of sodium hydroxide which has been dissolved in 62.5 g of water at 50°C to hydrolyse and neutralise the tocopheryl phosphates. The product was cooled

to ambient temperature then further cooled with liquid nitrogen to give a brittle product that was ground to a powder and dried under vacuum.

The mole ratio of mono-tocopheryl phosphate to di-tocopheryl phosphate was approximately 70:30. The product contained mono and di sodium tocopheryl phosphate (approx. 65-85% by mole), sodium di-tocopheryl phosphate (approx. 10-35% by mole) and some sodium di-tocopheryl pyrophosphate.

Preparation and application of the topical formulation

The dried powder was dispersed in water as a 5% solution. 10 ml of this solution was applied to the hands to give a satisfactory application of the tocopheryl phosphates to the skin.

10 **Example 2**

The skin penetration properties of a mixture of mono- and di-tocopheryl phosphates according to the invention were compared to tocopheryl acetate.

Test formulations

The test materials are made up on the basis of 5% mixed actives (mono-tocopheryl phosphate (TP), di-tocopheryl phosphate (T2P) or tocopheryl acetate) in a vehicle consisting of 95/5 distilled water/ethanol with pH adjusted (if necessary to 6.5-7.0 with citric acid or dilute NaOH).

TP and T2P (mixed sodium salts)

A slurry of 6.25 w/w % of 80% mixed TP and T2P in 93.75 w/w % of the 95/5-water/ethanol mixture was prepared.

Active	TP & T2P (micrograms per applied dose)
tocopheryl phosphate	252
di-tocopheryl phosphate	1194
tocopherol	24

TP and T2P complexed

The TPC used was lauryl-imino di-propionic acid tocopheryl phosphate, a surface-active amphoteric phosphate ester complex formed from lauryl imino propionic acid (Deriphat 160) and tocopheryl phosphates. The solution was based on 40% active mixed phosphates as the latter is reacted/combined in a 60/40-amphoteric/mixed-phosphate weight ratio (1.9-1 mole ratio). 12.5 w/w % of the complex was dissolved in 87.5 w/w % of 95/5 water/ethanol mixture.

Active	TP and T2P complexed (micrograms per applied dose)
tocopheryl phosphate	188
di-tocopheryl phosphate	713
Tocopherol	20

10 Tocopheryl Acetate

Tocopheryl acetate is obtained from Roche/BASF. 5.0 w/w % of tocopheryl acetate was dispersed in 95.0 w/w % of 95/5 water/ethanol mixture.

Method

The test formulations are evaluated in *in vitro* human skin penetration studies. Samples are analyzed for the mono- and di-tocopheryl phosphates, free alpha-tocopherol, and tocopheryl acetate by high performance liquid chromatography (HPLC). The tests are conducted by DermTech International (San Diego, CA). Human cadaver skin samples are obtained and prepared. Each formulation is evaluated on triplicate sections from each donor at a topically applied dose of 5 $\mu\text{L}/\text{cm}^2$. Receptor solutions are collected over 48 hours at pre-selected time intervals. After 48 hours the skin surface is washed with isopropyl alcohol, and the skin is collected and split into epidermis and dermis. The skin sections are extracted with isopropyl alcohol. All collected samples are processed and assayed for tocopherol, tocopheryl acetate, tocopheryl phosphate and di-tocopheryl phosphate.

Mass balance from the samples is between 80-120% of the applied dose.

No tocopherols are observed in the receptor solution. This could be a result of amounts being below limits of detection, or degradation of the various tocopherol species into other, as yet uncharacterized, compounds.

TABLE 1 :SKIN PENETRATION STUDY
(Percent Distribution of Tocopherols Recovered; wt/wt %).

5

Treatment	α -Tocopherol	TP	T ₂ P
TP & T2P (mixed sodium salts)			
Surface wash	65.05	41.40	56.05
Epidermis	26.74	47.06	37.31
Dermis	8.24	11.42	6.62
Dermis/Epidermis Ratio	0.31	0.24	0.18
TP & T2P complexed			
Surface wash	50.00	48.82	70.92
Epidermis	35.99	24.55	16.67
Dermis	14.07	26.62	12.36
Dermis/Epidermis Ratio	0.39	1.08	0.74
Tocopherol Acetate	α -Tocopherol	—	—
Surface wash	91.48		
Epidermis	7.13		
Dermis	1.39		
Dermis/Epidermis Ratio	0.20		

Conclusions

The results demonstrate that the inclusion of 20 to 30% of T2P in the formulation did not have a deleterious effect on the performance of the tocopheryl phosphate product. Further, both of the TP/T2P mixtures were more efficiently transported into the dermis than the tocopheryl acetate product.

Example 3

In this example, a mixture was prepared comprising mono-ubiquinyl phosphate and di-ubiquinyl phosphate made according to the invention.

100g of ubiquinone was partially dissolved in 200ml of hot glacial acetic acid. To the
5 vigorously stirred solution, small amounts of zinc (total of 30g) were added until the solution
changed from yellow to green and then became colorless. The hot solution was filtered and
the unreacted zinc was washed 2 more times (50ml) with hot glacial acetic acid to recover any
remaining ubiquinol. Glacial acetic acid was removed from the ubiquinol by vacuum
distillation or by cooling the solution to 0°C and filtering off the crystallized ubiquinol. To
10 further remove any traces of acetic acid, the ubiquinol was placed under high vacuum (1mm
Hg) for a period of 2 hours.

The ubiquinol product was treated immediately by heating to 100°C and adding 33g of P_4O_{10} .
The mixture was stirred for 3 hours and then 500 ml water was introduced slowly into the
mixture. The temperature of the reaction was maintained just below boiling point for a
15 further 1 hour. Removal of water yielded ubiquinyl phosphates and phosphoric acid. The
phosphoric acid was partially removed by further washes with hot water.

The final product consisted of 139g of mono-ubiquinyl phosphate, di-ubiquinyl phosphate
and phosphoric acid. The product was analyzed by ^{31}P NMR and the molar ratio of mono-
ubiquinyl phosphate : di-ubiquinyl phosphate was 76:24.

20 Example 4

In this example, the surface active properties of mono-tocopheryl phosphate was investigated.
0.1 g of pure di-sodium mono-tocopheryl phosphate was dissolved in 10 ml of pure distilled
water in a 50 ml cylindrical stoppered vessel. The vessel was shaken on a test tube agitator
and the headspace filled with stable foam. The foam was examined on a daily basis and
25 showed complete stability for one day and then slowly degraded over the rest of the four-day
period.

Mono-tocopheryl phosphate is therefore a surface active agent with detergent properties.

The word 'comprising' and forms of the word 'comprising' as used in this description and in
the claims does not limit the invention claimed to exclude any variants or additions.

Modifications and improvements to the invention will be readily apparent to those skilled in the art. Such modifications and improvements are intended to be within the scope of this invention.

WHAT IS CLAIMED IS:

1. An emulsion composition for therapeutic administration comprising:
 - (a) at least one mono-electron transfer agent phosphate derivative;
 - (b) at least one di-electron transfer agent phosphate derivative;
- 5 wherein the amount of mono-electron transfer agent phosphate derivative is no less than equimolar to the amount of di-electron transfer agent phosphate derivative; and
 - (c) a suitable carrier.
2. A composition according to claim 1 wherein the molar ratio of mono-electron transfer agent phosphate derivative to di-electron transfer agent phosphate derivative is in the
10 range from 85:15 to 65:35.
3. A composition according to claim 1 wherein the mono-electron transfer agent phosphate derivative and the di-electron transfer agent phosphate derivative are derived from alpha-tocopherol.
4. A composition according to claim 1 wherein the mono-electron transfer agent
15 phosphate derivative and the di-electron transfer agent phosphate derivative are complexed with a complexing reagent selected from amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.
5. A method for administering to a subject phosphate derivatives of electron transfer
20 agent comprising the step of administering an emulsion composition comprising the following:
 - (a) at least one mono-electron transfer agent phosphate derivative;
 - (b) at least one di-electron transfer agent phosphate derivative;
- 25 wherein the amount of mono-electron transfer agent phosphate derivative is no less than equimolar to the amount of di-electron transfer agent phosphate derivative; and
 - (c) a suitable carrier.
6. A process for preparing a therapeutic formulation containing phosphate derivatives of electron transfer agents comprising the steps of:

Box 1 Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1,2,4-6
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The claims are so broad in scope that a complete search is not possible. Claims 1,2,4,5 and 6 relate to a composition comprising at least one mono-electron transfer agent phosphate derivative and at least one di-electron transfer agent phosphate derivative. The claims cover a very broad range of compounds where as the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case a complete search over the whole of the claimed scope is not feasible. Consequently the search has been carried out for those parts of the claims which appear to be supported and disclosed such as the examples disclosed in the description with due regards to the general idea underlying the application.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU01/01475

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5387579A (MEYBECK et al.) 7 February 1995 Abstract and Examples	8
X	Derwent Abstract Accession No. 98-071819/07. Class B02 D21, JP 0930813A (NONO GAWA SHOJI KK) 2 December 1997 Abstract	8
A	STN File CA, Abstract 111:45280, + JP 1986-2817293 (SHISEIDO CO. LTD et al.), 2 December 1986 Abstract	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU01/01475

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	6046181	CN	1173869	EP	798305	US	5965750
		WO	9714705				
US	5387579	CA	2075201	EP	513104	EP	652010
		FR	2657526	US	5656618	US	5952001
		WO	9111189				

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)